Subscribe Now Subscribe Today
Science Alert
 
Blue
   
Curve Top
International Journal of Pharmacology
  Year: 2015 | Volume: 11 | Issue: 3 | Page No.: 243-247
DOI: 10.3923/ijp.2015.243.247
 
Facebook Twitter Digg Reddit Linkedin StumbleUpon E-mail

Annotation of Camel Genome for Estimation of Drug Binding Power, Evolution and Adaption of Cytochrome P450 1a2

Yousef Altaher, Masayuki Nakanishi and Mahmoud Kandeel

Abstract:
While camels rapidly evoluted several genes to adapt their environment, contemporary studies recorded that camels are sensitive to toxicity with some drugs as monensin, narasin and maduramicin ionophores compounds, which are extensively used in veterinary medicine. Recently, camel genome was resolved, which will allow for discovery of secrets of camel life. To this end, it is not known whether camel cytochrome enzymes were specially developed or adapted to camel environment or it has been associated with increasing the susceptibility of camels to toxicity with drugs. The objectives of this work are annotation of camel genome and retrieval of camel for cytochrome P450 1A2 (CYP 1A2) for phylogenetic, molecular modeling studies, docking studies and determination of its drug binding power. Results indicated poor efficiency of camel CYP 1A2 in binding with drugs. Furthermore, despite the high evolution of many camel genes to adapt camel environment, CYP 1A2 was found to be phylogenetically retarded gene showing lower rate of evolution compared with subset of data from 100 different organisms. These results suggests the potential toxicity of camels with drugs undergoing oxidation by CYP 1A2.
PDF Fulltext XML References Citation Report Citation
How to cite this article:

Yousef Altaher, Masayuki Nakanishi and Mahmoud Kandeel, 2015. Annotation of Camel Genome for Estimation of Drug Binding Power, Evolution and Adaption of Cytochrome P450 1a2. International Journal of Pharmacology, 11: 243-247.

DOI: 10.3923/ijp.2015.243.247

URL: https://scialert.net/abstract/?doi=ijp.2015.243.247

COMMENT ON THIS PAPER
 
 
 

 

 
 
 
 
 
 
 
 
 

 
 
 
 
 
 
 
 
 
 
 

Curve Bottom